Erratum for Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

In the article by Hochhaus et al entitled “Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy,” which appeared in the March 15, 2007, issue of Blood (Volume 109:2303–2309), Table 2 contains an incorrect parenthetical percentage. The percentage rate of CHR for the imatinib-intolerant disease cohort at 8 months should be 97%. (The number of patients exhibiting CHR is accurate at 57.)